The selectivity of electron acceptors for the removal of caffeine, gliclazide, and prazosin in an up-flow anaerobic sludge blanket (UASB) reactor

• Main Authors: Azizan, Nur Alyaa Zahida, Kamyab, Hesam, Yuzir, Ali, Abdullah, Norhayati, Vasseghian, Yasser, Ali, Ismat H., Elboughdiri, Noureddine, Sohrabi, Mohsen
• Format: Article
• Published: Elsevier Ltd 2022
• Subjects: T Technology (General)
• Online Access: http://eprints.utm.my/103186/; http://dx.doi.org/10.1016/j.chemosphere.2022.134828
• Institution: Universiti Teknologi Malaysia

This study attempts to investigate the relationship between the dominance of reducing conditions and the biotransformation of pharmaceutical compounds, which has been scarcely reported in a continuous anaerobic treatment process. Previous batch experiments have discovered the possible implications of different reducing conditions on the biotransformation process, but have failed to reflect actual removal performance due to substrate limitations and other operational factors. Continuously operating reactors commonly receive wastewater stream containing a wide range of electron acceptors that diversify the growth of microorganisms in anaerobic treatment. The alteration of the dominance of reducing conditions in a continuous anaerobic reactor may result in the improvement of biotransformation performance compared to a single reducing condition in a substrate-limited batch experiment. The removal of psychostimulant caffeine (CAF), anti-diabetic drug gliclazide (GCZ), and anti-hypertensive drug prazosin (PRZ) were examined through the operation of an up-flow anaerobic sludge blanket (UASB) reactor under predominant methanogenic condition (Phase I) and simultaneous reducing conditions provided by a nitrate supplement (Phase II). The results revealed high biotransformation performance for all three compounds (73-> 99%) in both Phase I and Phase II experiments and fitted the pseudo-first-order model. The biotransformation rate of CAF and PRZ were relatively lower by 25% and 29%, while the GCZ rate improvement doubled in Phase II compared to Phase I. The outcome from 16s rRNA sequencing suggested that the biotransformation of the compounds may be driven by Firmicutes and Bacteroidota in both phases, and Burkhorderiales and sulfate-reducing bacteria species in Phase II. This study proved preferential of reducing conditions does not negatively affect the biotransformation performance of each pharmaceutical compound in a continuous anaerobic reactor, but they led to varying biotransformation rate, hence shifting the microbial diversity.